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Abstract 
Objective:  To describe the characteristics and management of Diabetes mellitus (DM) patients from 
low- and middle-income countries (LMIC).  
Methods: We systematically characterized consecutive DM patients attending public health services 
in urban settings in Indonesia, Peru, Romania and South Africa, collecting data on DM treatment 
history, complications, drug treatment, obesity, HbA1c, and cardiovascular risk profile; and assessing 
treatment gaps against relevant national guidelines.   
Results: Patients (median 59 years, 62.9% female) mostly had type 2 diabetes (96%), half for >5 
years (48.6%). Obesity (45.5%) and central obesity (females 84.8%; males 62.7%) were common. The 
median HbA1c was 8.7% (72 mmol/mol), ranging from 7.7% (61 mmol/mol; Peru) to 10.4% (90 
mmol/mol; South Africa). Antidiabetes treatment included metformin (62.6%), insulin (37.8%), and 
other oral glucose-lowering drugs (34.8%). Disease complications included eyesight problems 
(50.4%), EGFR <60 ml/min (18.9%), heart disease (16.5%), and proteinuria (14.7%). Many had an 
elevated cardiovascular risk with elevated blood pressure (36%), LDL (71.0%), and smoking (13%), 
but few were taking antihypertensive drugs (47.1%), statins (28.5%) and aspirin (30.0%) when 
indicated. Few patients on insulin (8.0%), statins (8.4%) and antihypertensives (39.5%) reached 
treatment targets according to national guidelines. There were large differences between countries 
in terms of disease profile and medication use.  
Conclusion: DM patients in government clinics in four LMIC with considerable growth of DM have 
insufficient glycemic control, frequent macrovascular and other complications, and insufficient 
preventive measures for cardiovascular disease. These findings underline the need to identify 
treatment barriers and secure optimal DM care in such settings. 
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INTRODUCTION 
Diabetes mellitus (DM) is one of the largest global health emergencies of the 21st century. In 2017, 
there were 425 million adults estimated to be living with DM, and this number is predicted to 
increase to 629 million by 2045 (1; 2). An estimated 80% of people with DM live in low- or middle-
income countries (LMICs) (2). Although studies are few, compared to those on individuals living in 
high-income countries,  DM patients in LMIC may present at a younger age or with more advanced 
disease and more disease complications (3). Health care access and long-term care may be more 
problematic, with inadequate access to laboratory testing, medication such as insulin, health 
information, and limited self-management of patients (4). Also, people living with DM in tropical 
countries may be at higher risk for infectious diseases (5). Cardiovascular complications, the leading 
cause of mortality and morbidity among patients with type 2 DM (6; 7), may also be more common 
among people living with DM in LMICs (8-10), due to higher rates of smoking, and less access to 
cardiovascular risk assessment and management (11-15). Assessment of diabetes disease 
characteristics, cardiovascular risk profile and medical management of people living with DM has 
been undertaken in some country-specific studies (16-18) and compared across LMIC countries in 
Asia and sub-Saharan Africa (12; 19; 20). Such studies are needed to help improve management of 
DM and reduce its progression and complications. 
 As part of the TANDEM project on DM and tuberculosis (21), we have systematically 
characterized people with DM in government health clinics or hospitals in Indonesia, Peru, Romania 
and South Africa, four countries that are witnessing a rapid growth of DM (1). The TANDEM project 
has examined the prevalence of tuberculosis among individuals with DM, but this also allowed us to 
characterize DM patients in these four countries. Thus, the objectives of the present study were: (1) 
to establish disease phenotype and cardiovascular risk profile of DM patients; (2) to characterise 
medical treatment, and gaps between national and international guidelines and actual patient care 
as a ‘cascade of care’, and (3) to identify possible socio-demographic factors associated with 
inadequately controlled DM or with sub-optimal management. 
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METHODS 
Setting and design 
This study is part of The Concurrent Tuberculosis and Diabetes Mellitus (TANDEM) study which aims 
to develop methods for better screening and management of combined tuberculosis and DM, and to 
increase basic knowledge about the link between the two diseases (21). TANDEM is a multicentre 
prospective study with field sites in Peru, Romania, South Africa and Indonesia, countries with 
diverse healthcare systems and population demographics, but all with a relatively high burden of 
tuberculosis and an increasing prevalence of DM (1; 22). The TANDEM study recruited 2096 
consecutive patients (December 2013 to June 2016) with previously diagnosed DM to be screened 
for tuberculosis through symptom screen, chest X-ray and sputum examination. To identify possible 
factors associated with tuberculosis, all patients were uniformly and systematically characterized in 
terms of DM disease characteristics and management. These data were used for the current study, 
excluding those patients in whom active tuberculosis was diagnosed.  
 In Indonesia, DM patients were recruited in 25 community health centres and from the 
endocrine clinic in a tertiary public referral hospital in Bandung. In Peru, patients were recruited at a 
diabetes clinic at one tertiary level public hospital in Lima, as diabetes care in the public domain is 
mainly provided by hospitals. In Romania, patients with DM were recruited from two secondary level 
hospitals in Craiova. In South Africa, patients were recruited at three community health centres in 
the northern Cape Town metropolitan area. For more details of study site selection and location see 
Supplementary File. 
 
Study procedures  
Patients with known DM (either under care for DM or on DM medication) who were above 18 years 
of age were eligible; those with gestational or steroid induced diabetes were excluded. Having 
obtained written informed consent, research doctors conducted an interview, using a validated 
questionnaire, with each patient asking about their socio-demographic characteristics (age, gender, 
and education, and assets to link to socio-economic status), behavioural characteristics such as self-
reported smoking status and alcohol consumption, and diabetes characteristics such as DM history, 
complications, medication, and management. Research nurses followed a standard operating 
procedure for taking patients’ blood pressure using a digital device, and for measuring height, 
weight (using digital scales), and waist measurement for calculation of body mass index (BMI) and 
central obesity. Venous blood was taken for laboratory glycated hemoglobin (HbA1c), and urine for 
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albumin to creatinine ratio (ACR). All HbA1c samples were analysed in an accredited laboratory with 
NGSP certification, using the HPLC methods according to WHO guidelines and with DCCT aligned 
assays. Lipid profile and creatinine, recorded as the most recent test undertaken within the previous 
month, was obtained from the medical records for a sub-set of patients. Laboratory methods for 
both LDL and HDL used Siemens dimension clinical chemistry system. Ethical approval was received 
from the Observational/Interventions Research Ethics Committee, London School of Hygiene and 
Tropical Medicine on 18 December 2013 (LSHTM ethics ref: 6449, LSHTM amendment no: A473) and 
Institutional Review Boards in Indonesia, Romania, Peru and South Africa. 
 
Data management and variables used 
Demographic and clinical data were entered onto a case report form and then into a secure, 
centrally managed, electronic database (REDCap). Other data, such as laboratory results, diabetes 
history, smoking status and complications were entered directly into REDCap. Data quality was 
checked on a monthly basis for accuracy and completeness.  
 
 Blood pressure was categorised according to the JNC VIII (23):  Normal (systolic and diastolic 
<120/80 mmHg); Pre-hypertension (systolic 120-139 or diastolic 80-89 mmHg); Stage I hypertension  
(systolic 140-159 or diastolic 90-99 mmHg); Stage II hypertension (systolic ≥160 or diastolic ≥100 
mmHg). Weight and height for Indonesian patients were classified based on the Asia Pacific Criteria 
of Body Mass Index (24): Under-weight (<18·5 kg/m2); Normal (18·5-22·9 kg/m2); Over-weight (23·0-
24·9 kg/m2); Obese I (25·0-29·9 kg/m2); Obese II (≥30 kg/m2). Weight and height for the three other 
sites were classified according to the World Health Organization (25): Under-weight (<18·5 kg/m2); 
Normal (18·5-24·9 kg/m2); Over-weight (25·0-29·9 kg/m2); Obese (≥30 kg/m2). Central obesity for 
female patients in all sites was categorized as a waist circumference (WC) of ≥80 cm. Central obesity 
for males was categorized as a WC ≥90 cm for Indonesia and Peru and ≥94cm for Romania and South 
Africa (26). Laboratory HbA1c was categorised into three groups <7·0; 7·0-9·9; ≥10% (<53; 53-85; ≥86 
mmol/mol) for analysis (27). ACR categories were normal (<30 µg/mg); moderately increased (30-
299 µg/mg), and albuminuria (≥300 µg/mg). Low-density lipoprotein (LDL) were categorized as 
dyslipidemia if the result was ≥100 mg/dL (2.6 mmol/l), or if high-density lipoprotein (HDL) was ≤40 
mg/dL (1.0 mmol/l) for males or ≤50 mg/dL (≤1.3 mmol/l) for females (27; 28). Estimated glomerular 
filtration rate (eGFR) was calculated according to the CKD-EPI creatinine equation 2009 (29). 
Principal Component Analysis (30) was performed to build a socio-economic status index based on 
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asset ownership by patients that included non-sellable (possession of a bank account, type of 
sanitation facility, household water source) and sellable assets (e.g. stove, refrigerator, washing 
machine, television).   
 
Diabetes mellitus treatment guidelines for the four countries 
The gap between optimal and actual treatment with insulin, antihypertensive, lipid-lowering and 
antiplatelet drugs was calculated using patient’s HbA1c, blood pressure, LDL and cardiovascular 
(coronary artery disease, myocardial infarction, angina) disease history. Among patients using 
insulin, antihypertensive and lipid-lowering drugs, HbA1c, blood pressure and LDL values were used 
to examine what proportion of patients reached desired treatment targets according to national 
guidelines (19; 27; 28; 31; 32): 
1. Patients with HbA1c ≥10% (86 mmol/mol) should have insulin added to their medications. 
2. Patients with blood pressure ≥140 systolic or ≥90 diastolic should be managed with anti-
hypertensive medication. 
3. Cardiovascular complications should be managed with aspirin. 
Macrovascular complications included infarct (coronary artery disease, angina, myocardial 
infarction), heart failure, cerebrovascular disease, peripheral vascular disease). Microvascular 
complications included a history of renal disease, neuropathy, eye problems (blindness, impaired 
vision, glaucoma, cataract).  
Statistical analysis 
Descriptive data are presented as mean and standard deviation for normally distributed data, 
median and inter-quartile range (IQR) for non-normally distributed data, and proportions for 
categorical data. Odds ratios and 95% confidence intervals were estimated using logistic regression 
to investigate factors associated with severe disease (defined as an HbA1c ≥10% (86 mmol/mol) or 
macrovascular or microvascular complications) and poor medical treatment (defined as patients not 
receiving insulin, anti-hypertensives or aspirin when it is indicated). We then undertook multiple 
logistic regression, including all the variables in the model. A test for trend was done for ordinal 
variables where the trend was consistent but no individual levels were statistically significant. 
Univariate and multivariate analysis was not undertaken for South Africa due to the small number of 
participants. All analyses were stratified by site, given the substantial heterogeneity expected. 
Statistical analyses were performed using STATA Version 12·1. 
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RESULTS 
General patient characteristics 
After excluding 28 DM patients with active tuberculosis, 2068 were included, in Indonesia (n=783), 
Peru (n=599), Romania (n=603), and South Africa (n=83). Baseline characteristics are shown in Table 
1. All patients in Peru and South Africa had type 2 DM, 98% in Indonesia and 87% in Romania. 
Almost half of the patients (49%) had had DM for at least five years. Their median age was 59 years, 
63% were female and 33% had an education of primary school or less.  
 
Glycemic control and diabetes complications  
The median HbA1c across all four sites was 8·7% (IQR 7·0-10·7%) (72; 53-93 mmol/mol). It was 
highest in South Africa (10·4%; 90 mmol/mol) and appeared lowest in Peru (7·7%; 61 mmol/mol), 
although HbA1c was missing for a substantial proportion of DM patients in Peru (Table 1; 
Supplementary Figure 1). The proportion of patients using metformin was 63% overall, with the 
greatest use in South Africa (90%), and the lowest in Indonesia (55%). Insulin, either alone or in 
combination with oral medication, was used by 38% of patients overall, with the highest use of 
insulin in Romania (67%) where patients were recruited in hospital wards, and the lowest in Peru 
(20%) (Table 1). Disease complications including heart disease, eyesight problems, micro- and 
macroalbuminuria, and decreased renal clearance were common across all populations (Table 1).  
 
Cardiovascular risk profile 
On average, patients had a moderately increased cardiovascular risk profile, as shown in Table 2. 
Overall, almost half of the DM patients had a BMI categorised as obese (46%). This was highest for 
the Indonesian cohort when using the Asia Pacific Criteria of BMI (Obese I, 39·3%; Obese II, 14·2%). 
Eighty-five percent of females and 63% of males across sites were categorised as having central 
obesity. Uncontrolled hypertension in patients not on anti-hypertensives, was reported in 36% of 
the overall cohort and this was highest in South African patients (52%) and lowest in patients in the 
Peru site (15%). Current smoking was reported in 13% of patients across all sites. In a subset of 
patients in three sites, dyslipidemia (LDL ≥100 mg/dL (2.6 mmol/l)), for patients not on statins, was 
reported in 74% (Indonesia 80%; Romania 55%; South Africa 52%).  
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Medical treatment 
Uptake of treatment and success in terms of reaching treatment targets was suboptimal, with large 
variation between sites. For instance, of patients with an indication for insulin (HbA1c ≥10%, 86 
mmol/mol),  55% were using insulin, varying from 80% in Romania, to 73% in South Africa, 41% in 
Peru, and 32% in Indonesia (Table 3). Of patients in these sites who were on insulin, only a small 
proportion had their HbA1c controlled to <7% (53 mmol/mol) (Table 4). Similarly, of 913 patients 
with hypertension, less than half (47%) were taking antihypertensive drugs (Table 3), while only 40% 
of 711 patients taking anti-hypertensive drugs had their blood pressure controlled (Table 4). Of 326 
patients reporting cardiovascular complications, 30% were on aspirin, ranging from 86% in South 
Africa to 20% in Indonesia (Table 3). Blood lipids were only available for a subset of patients, and not 
for patients in Peru. Of 267 patients with dyslipidemia (LDL ≥100 mg/dL (2.6 mmol/l)), 29% were 
treated with statins (Table 3). Of 407 patients who were taking statin medication, only 8% had a LDL 
level of less than 100 mg/dL (2.6 mmol/l) (Table 4). 
 
Factors associated with disease severity and medical treatment 
Disease severity and medical treatment and underlying factors differed substantially between 
countries. We assessed risk factors for disease severity as defined separately by a high HbA1c, 
macrovascular or microvascular complications (Supplementary Tables S1-3). Older age was 
associated with macrovascular complications in Indonesia (OR 1.50; 95% CI 1.02-2.20) and Romania 
(OR 2.52; 95% CI 1.65-3.87) but not in Peru (OR 1.41; 95% CI 0.74-2.69), and with lower HbA1c in 
Indonesia (OR 0.45; 95% CI 0.32-0.64), but not in Romania (OR 0.83; 95% CI 0.57-1.21) or Peru (OR 
0.61; 95% CI 0.35-1.06). Males were more likely to have macrovascular complications in Indonesia 
(OR 1.81; 95% CI 1.24-2.63). Longer DM duration was associated with more macro- and 
microvascular complications in Romania (6-15 years: OR 2.59; 95% CI 1.35-4.99, and OR 2.11; 95% CI 
1.33-3.37, respectively; >15 years DM duration: OR 4.23; 95%CI 2.09-8.55, and OR 7.06; 95% CI 3.81-
13.07, respectively), and with more microvascular complications in Indonesia (6-15 years: OR 1.75; 
95% CI 1.09-2.81; >15 years: OR 3.72; 95% CI 1.94-7.13) and Peru (>15 years: OR 2.07; 95% CI 1.02-
4.18). Completed high school education and Q3 socioeconomic status were associated with lower 
HbA1c in Romania (OR 0.43; 95% CI 0.24-0.79 and OR 0.56; 95% CI 0.33-0.97, respectively). 
Completed high school education was associated with less microvascular complications in Peru (OR 
0.44; 95% CI 0.27-0.73) and Romania (OR 0.43; 95% CI 0.23-0.80), but not Indonesia (OR 1.08; 95% CI 
0.71-1.66).  
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 We assessed what factors were associated with non-compliance to treatment guidelines with 
regard to use of insulin, anti-hypertensives and aspirin (Supplementary Tables S4-6). Compared to 
females, males were more likely to take insulin in Indonesia (OR 2.26; 95% CI 1.16-4.42), but less 
likely to take anti-hypertensives when indicated (OR 0.43; 95% CI 0.26-0.70). Older-aged patients 
were more likely to be taking anti-hypertensives in Indonesia (OR 2.29; 95% CI 1.44-3.62), but were 
less likely to be taking aspirin for cardiovascular complications in Romania (OR 0.34; 95% CI 0.13-
0.86). DM duration of 6-15 years was associated with increased likelihood of taking insulin in 
Indonesia (OR 2.70; 95% CI 1.05-6.96) and Romania (OR 2.35; 95% CI 1.09-5.03), and of taking anti-
hypertensives in Peru (OR 5.73; 95% CI 1.30-25.13). No significant associations were found between 
education or socioeconomic status.  
 
DISCUSSION 
Numerous studies have addressed the growing burden of diabetes in low- and middle- income 
countries but detailed patient data like disease complications and specific drug treatment have 
mostly been reported in single-site studies. In the context of the TANDEM project on the interaction 
between diabetes and tuberculosis (21), we have pooled systematically collected detailed 
characteristics of more than 2000 DM patients from Indonesia, Peru, Romania and South Africa. 
Three main conclusions could be drawn. First, both among hospitalised and ambulatory patients in 
these four countries, glycemic control is often poor, disease complications are common, and the 
cardiovascular risk is often high. Second, across different settings many patients who qualify for 
insulin, anti-hypertensive, lipid-lowering drugs or aspirin do not receive these drugs. Third, of those 
on these drugs, only a minority reach desired treatment targets. These findings underline the need 
to identify treatment barriers and secure optimal DM care in low- and middle-income countries 
where most people with DM live. 
 Recent studies have addressed the ‘cascade of care’ for diabetes (19; 20; 33). For instance, 
based on population surveys in 12 sub-Saharan African countries it was estimated that only 37% of 
DM patients were aware of their diagnosis, and only 11% received medication (19). But these studies 
have also stressed the lack of data regarding the burden of diabetes-related complications. 
Systematically collecting data from individual patients we could precisely characterize disease 
severity, complications and drug treatment. With regard to disease severity, hyperglycemia was 
common yet use of insulin was low. Poor glycemic control in Romania could be due to a selection 
bias as only in-patients were investigated, who are more likely to have poor disease management or 
infections or other disease complications leading to hyperglycemia. Among ambulatory patients in 
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the others sites the proportion of patients with an HbA1c <7% (53 mmol/mol) ranged from 11% to 
28%. Moreover, from discussion with local practitioners and evaluation of patient records it became 
clear that HbA1c was not routinely measured, and in Peru even during this study it proved 
impossible in a large proportion of patients due to the local unavailability of HbA1c tests. Lack of 
HbA1c monitoring probably contributes to poor glycemic control. Other factors include insufficient 
or inadequate use of insulin, which is often not available (34), too expensive, or difficult to use 
because of patients unwillingness or inability to do self-monitoring of blood glucose (35). Even 
metformin and sulphonylurea derivates, widely used and cheap diabetes drugs, are often not 
available or prohibitively expensive (36; 37).  
 Like poor glycemic control, disease complications as reported in other studies (7; 9; 38; 39), 
were common, with many patients suffering from cardiovascular disease, eyesight problems and 
renal disease. Local health providers may not be fully aware of disease severity of their patients, 
because time and resources are often lacking to conduct systematic assessment (14; 40), as was 
done in this study. Our study may even underestimate the proportion of patients with disease 
complications as we mainly relied on patient history and medical records and did not perform 
electrocardiography, fundoscopy, or other related tests. Our cross-sectional study was unable to 
establish what proportion of complications were already present at the time of initial presentation, 
and how often complications develop while patients are under DM care, as a result of insufficient 
glycemic control and cardiovascular risk management. It is clear that both earlier detection of DM 
and better glycemic control and cardiovascular risk management are needed.  
 Cardiovascular risk profile was elevated in most patients. Obesity, uncontrolled hypertension 
and dyslipidemia were common. The proportion of patients smoking was less than we had expected, 
ranging from 6% in Peru, 14% in Indonesia, 16% in Romania and 37% in South Africa. It is possible 
that patients may have given socially-desirable answers, particularly as a much higher proportion 
reported having stopped smoking in most sites. Also, in these countries, smoking is more common 
among men, while almost two-thirds of study patients were female. 
 We found large discrepancies between guidelines and practice regarding use of insulin and 
cardiovascular risk management. Approximately half of those patients qualifying for insulin or 
antihypertensive drugs received these drugs. Similarly, of those with an indication for statins, or 
aspirin as secondary prevention of cardiovascular disease, only 30% were prescribed these drugs. 
And of those who were prescribed these drugs, targets in terms of HbA1c, blood pressure and LDL 
were only met for 8%, 40%, and 8% respectively. This could be due to incomplete treatment 
adherence, which was not assessed in this study, or insufficient dosing. Optimal glycemic control 
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with insulin is difficult to achieve without self-monitoring of blood glucose, but this is not routine in 
government clinics in any of the four sites. Similary, self-measurement of blood pressure is rarely 
done, and blood pressure is not measured at each clinic. Limited time and space in clinics, or low 
awareness or lack of training among health professionals may contribute to the poor ‘cascade of 
care’ in DM care in low-resource settings (14; 38; 40; 41). 
 This study suffers from limitations. As it was a cross-sectional study of patients who had had DM 
for a median of 5 years or more we do not know how many patients present with complications, and 
how many patients die from DM over time or disengage from DM care. Second, it is unlikely that our 
data are fully representative of the four countries. Assessment of the DM phenotype and treatment 
was not a primary objective of TANDEM, and patients were only recruited in a limited number of 
clinics. In Romania, we only included inpatients, who likely suffer from poorer glycemic control and 
more disease complications. Third, complications were mostly self-reported. It would have been 
preferable to have a formal assessment by a cardiologist, neurologist and eye physician but this was 
beyond the scope of this study. Fourth, for some characteristics there was a lot of missing data. For 
instance, recent lipid measurements, not included in the TANDEM assessment, but extracted from 
patient records, were not available in Peru, and only in a minority of patients from the other sites, 
and HbA1c was often missing in Peru and South Africa most likely due to frequent unavailability of 
laboratory tests. Lack of coverage from public health insurance or unawareness among health 
professionals may also be involved.  
 Despite these limitations we feel that our study, using a standardised method and addressing 
the most important disease and treatment characteristics, shows a clear picture of the severity of 
DM in these countries across four continents and of the unmet needs in terms of drug treatment. 
Future studies should examine these issues longitundinally, identify barriers to optimal DM care, and 
evaluate possible interventions to help improve the outcome of DM patients.  
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Table 1. General characteristics of patients with diabetes according to recruitment site 
 Total 
(n=2068) 
n (%) 
Indonesia
(n=783) 
n (%) 
Peru
(n=599) 
n (%) 
Romania 
(n=603) 
n (%) 
South Africa
(n=83) 
n (%) 
Female sex 1301 (62.9) 500 (63.9) 426 (71.1) 321 (53.2) 54 (64.1) 
Age, median (IQR) 59 (52-66) 59 (53-65) 59 (52-
67) 
59 (51-66) 53 (47-60)
Education   
<Primary/no formal education 687 (33.4) 235 (30.0) 304 (50.8) 84 (14.2) 61 (74.4) 
Secondary school completed 473 (23.0) 146 (18.6) 112 (18.7) 201 (33.9) 14 (17.1) 
High school completed 641 (31.2) 226 (28.9) 163 (27.3) 247 (41.7) 5 (6.1) 
College/university/post 
graduate  
258 (12.5) 176 (22.5) 19 (3.2) 61 (10.3) 2 (2.4) 
n/a* 12 0 1 10 1 
Socio-economic status   
Q1: poorest 222 (10.9) 96 (12.4) 82 (13.7) 43 (7.3) 1 (1.2) 
Q2: poor 332 (16.2) 111 (14.4) 121 (20.2) 93 (15.7) 7 (8.6) 
Q3: middle income 378 (18.5) 121 (15.7) 126 (21.1) 119 (20.1) 12 (14.8) 
Q4: upper middle income  477 (23.3) 179 (23.2) 123 (20.6) 148 (25.0) 27 (33.3) 
Q5: richest 635 (31.1) 265 (34.3) 146 (24.4) 190 (32.0) 34 (42.0) 
n/a* 24 11 1 10 2 
Use of alcohol  660 (31.9) 14 (1.7) 288 (48.1) 338 (56.1) 21 (25.3) 
Duration of diabetes   
<1 year 388 (18.8) 138 (17.6) 126 (21.1) 122 (20.3) 2 (2.5) 
1-5 years 672 (32.6) 298 (38.1) 237 (39.6) 110 (18.3) 27 (33.3) 
6-15 years 704 (34.1) 280 (35.8) 139 (23.2) 249 (41.4) 36 (44.4) 
>15 years 299 (14.5) 67 (8.6) 96 (16.1) 120 (20.0) 16 (19.8) 
n/a* 5 0 1 2 2 
HbA1c,† Median % 
                IQR %  
8.7  
(7.0-10.7) 
8.3 
(6.7-10.2) 
7.7 
(6.2-10.1) 
9.5 
(8.1-11.3) 
10.4  
(9.0-12.0) 
              Median (IQR) 
mmol/mol 
72 (53-93) 67 (50-88) 61 (44-
87) 
80 (65-100) 90 (75-108)
HbA1c   
<7% (53 mmol/mol) 433 (24.3) 220 (28.2) 144 (38.0) 65 (11.1) 4 (11.1) 
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CAD: coronary artery disease; DM: Diabetes mellitus; eGFR: estimated glomerular filtration rate 
mL/min/1.73 m2; IQR: Interquartile range; MI: myocardial infarction; n/a =not available 
* Denominator for proportions does not include the number not available.  
† Data available for a total of 1783 patients: 780 Indonesia; 379 Peru; 588 Romania; 36 South Africa.  
‡ Patients may be in more than one category   
7-9.9% (53-85 mmol/mol)   757 (42.5) 339 (43.5) 137 (36.2) 271 (46.1) 10 (27.8) 
≥10% (65 mmol/mol) 593 (33.3) 221 (28.3) 98 (25.9) 252 (42.9) 22 (61.1) 
n/a* 285 3 220 15 47 
Diabetes medication‡   
No medication  180 (8.7) 63 (8.1) 87 (14.5) 29 (4.8) 1 (1.2) 
Insulin  781 (37.8) 223 (28.5) 120 (20.0) 406 (67.3) 32 (38.6) 
Metformin 1295 (62.6) 431 (55.0) 391 (65.3) 398 (66.0) 75 (90.4) 
Other oral DM drugs 720 (34.8) 357 (45.6) 91 (15.2) 248 (41.1) 24 (28.9) 
Comorbidities and 
complications‡  
  
Infarct (CAD, angina, MI) 326 (15.8) 140 (17.9) 46 (7.7) 133 (22.1) 7 (8.4) 
Heart failure  14 (0.7) 13 (1.7) 1 (0.2) 0 (0.0) 0 (0.0) 
Cerebrovascular disease 7 (0.3) 0 (0.0) 3 (0.5) 0 (0.0) 4 (4.8) 
Peripheral vascular disease 27 (1.3) 20 (2.6) 0 (0.0) 6 (1.0) 1 (1.2) 
Kidney disease 31 (1.5) 21 (2.7) 7 (1.2) 3 (0.5) 0 (0.0) 
Eye problems attributable to 
DM 
1043 (50.4) 272 (34.7) 463 (77.3) 258 (42.8) 50 (60.2) 
Renal Clearance    
eGFR ≥60 949 (81.1) 216 (73.5) 184 (82.9) 502 (83.3) 47 (92.2) 
eGFR 30-59 174 (14.9) 56 (19.0) 30 (13.5) 85 (14.1) 3 (5.9) 
eGFR <30 47 (4.0) 22 (7.5) 8 (3.6) 16 (2.6) 1 (1.9) 
n/a* 898 489 377 0 32 
Urine albumin/creatinine 
ratio  
  
<30 ug/mg 854 (60.2) 387 (50.0) n/a 422 (71.0) 45 (90.0) 
30-299 ug/mg 356 (25.1) 230 (29.7) n/a 121 (20.4) 5 (10.0) 
   ≥300 ug/mg 208 (14.7) 157 (20.3) n/a 51 (8.6) 0 (0.0) 
    n/a* 51 9 9 33 
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Table 2. Cardiovascular risk profile and medication management of patients according to 
recruitment site 
 Total
(n=2068) 
n (%) 
Indonesia
(n=783) 
n (%) 
Peru
(n=599) 
n (%) 
Romania 
(n=603) 
n (%) 
South 
Africa 
(n=83) 
n (%) 
Body Mass Index (kg/m2)*   
Underweight 42 (2.0) 24 (3.1) 4 (0.7) 14 (2.4) 0 (0.0) 
Normal  503 (24.4) 191 (24.4) 186 (31.2) 111 (18.6) 15 (18.5) 
Overweight 577 (28.0) 149 (19.0) 210 (35.2) 188 (31.5) 30 (37.0) 
Obese 936 (45.5) 419 (53.5) 197 (33.0) 284 (47.6) 36 (44.4) 
n/a† 10 0 2 6 2 
Central Obesity   
Females  1099/1296
(84.8) 
347/500 
(69.4) 
408/426 
(95.7) 
292/317 
(92.1) 
52/53  
(98.1) 
Males  476/759
(62.7) 
108/283 
(38.2) 
131/173 
(75.7) 
217/275 
(78.9) 
20/28  
(71.4) 
BP classification: patients not 
on anti-hypertensives‡  
  
Normal  357 (26.3) 104 (17.8) 196 (42.2) 54 (19.7) 3 (8.6) 
Pre-hypertension  517 (38.1) 182 (31.2) 198 (42.7) 123 (44.9) 14 (40.0) 
Stage I hypertension  308 (22.7) 176 (30.1) 45 (9.7) 77 (28.1) 10 (28.6) 
Stage II hypertension  175 (12.9) 122 (20.9) 25 (5.4) 20 (7.3) 8 (22.9) 
BP classification: patients on 
anti-hypertensives‡ 
  
Normal  73 (10.3) 13 (6.5) 22 (16.3) 35 (10.6) 3 (6.3) 
Pre-hypertension  208 (29.3) 45 (22.6) 54 (40.0) 96 (29.2) 13 (28.1) 
Stage I hypertension  212 (29.8) 58 (29.2) 34 (25.2) 105 (31.9) 15 (31.3) 
Stage II hypertension  218 (30.7) 83 (41.7) 25 (18.5) 93 (28.3) 17 (35.4) 
Dyslipidemia (mg/dl): patients 
not on statins 
  
LDL ≥100 (2.6 mmol/l) 191/260
(73.5) 
159/200 
(79.5) 
n/a 16/29  
(55.2) 
16/31  
(51.6) 
HDL ≤40 (male); ≤50 (female) 127/261 93/200 n/a 15/28 19/33 
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BMI: Body mass index (kg/m2); BP: Blood pressure; HDL: High density lipoprotein; LDL: Low density 
lipoprotein; WC: Waist circumference, n/a =not available   
* Body Mass Index (kg/m2) was classified as: 
• Underweight (<18.5) 
• Normal (18.5-22.9 Indonesia; 18.5-24.9 Peru, Romania, South Africa) 
• Overweight (23.0-24.9 Indonesia; 25.0-29.9 Peru, Romania, South Africa) 
• Obese (≥25.0 Indonesia; ≥30 Peru, Romania, South Africa) 
† Denominator for proportions does not include the number not available 
‡ Blood pressure classification according JNC VII: 
• Normal = systolic and diastolic <120/80 mmHg;  
• Pre-hypertension = systolic 120-139 or diastolic 80-89 mmHg;  
• Stage I hypertension = systolic 140-159 or diastolic 90-99 mmHg; 
• Stage II hypertension = systolic ≥160 or diastolic ≥100 mmHg.  
(1 mmol/l (male); 1.3 (female))  (48.7) (46.5) (53.6) (57.6) 
Dyslipidemia (mg/dL): patients 
on statins 
  
LDL ≥100 (2.6 mmol/l) 76/107
(71.0) 
59/66
(89.4) 
n/a 11/24 
(45.8) 
6/17  
(35.3) 
HDL ≤40 (male); ≤50(female)  
(1 mmol/l (male); 1.3 (female)) 
65/107
(60.7) 
29/66
(43.9) 
n/a 21/24 
(87.5) 
15/17 
(88.2) 
Smoking status   
Current 269 (13.0) 112 (14.3) 34 (5.7) 93 (15.5) 30 (36.6) 
Past 630 (30.5) 223 (28.5) 221 (37.0) 172 (28.6) 14 (17.1) 
Never 1165 (56.4) 448 (57.2) 343 (57.4) 336 (55.9) 38 (46.3) 
n/a† 4 0 1 2 1 
Anti-hypertensive drugs 711 (34.4) 199 (25.4) 135 (22.5) 329 (54.6) 48 (57.8) 
Lipid-lowering drugs (statins) 407 (19.7) 146 (18.6) 36 (6.0) 201 (33.3) 24 (28.9) 
Anti-platelet drugs (aspirin) 249 (12.0) 47 (6.0) 53 (8.9) 121 (20.1) 28 (33.7) 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 3. Treatment indication and actual treatment with insulin, antihypertensive, antiplatelet, and 
lipid-lowering medication according to recruitment site 
 Total
n/N (%) 
Indonesia
n/N (%) 
Peru
n/N (%) 
Romania 
n/N (%) 
South 
Africa 
n/N (%) 
HbA1c ≥10 (86 mmol/mol)*  593/1783
(33.3) 
221/780
(28.3) 
98/379
(25.9) 
252/588 
(42.9) 
22/36 
(61.1) 
Patients with HbA1c≥10 (86 
mmol/mol) receiving insulin 
325/593
(54.8) 
70/221
(31.7) 
40/98
(40.8) 
199/252 
(80.0) 
16/22 
(72.7) 
   
Hypertension†  913/2068
(44.1) 
439/783
(56.1) 
129/599
(21.5) 
295/603 
(48.9) 
50/83 
(59.5) 
Patients with hypertension  
taking anti-hypertensives  
430/913
(47.1) 
141/439
(32.1) 
59/129
(45.7) 
198/295 
(67.1) 
32/50 
(64.0) 
   
Cardiovascular complications‡  326/2068
(15.8) 
140/783
(17.9) 
46/599
(7.7) 
133/603 
(22.1) 
7/83 
(8.4) 
Patients with cardiovascular 
complications taking aspirin 
98/326
(30.0) 
28/140
(20.0) 
21/46
(45.6) 
43/133 
(32.3) 
6/7 
(85.7) 
   
LDL ≥100mg/dL (2.6 mmol/l)/§ 267/367
(72.8) 
218/266
(82.0) 
n/a 27/53 
(50.9) 
22/48 
(45.8) 
Patients with LDL ≥100mg/dL 
         (2.6 mmol/l) taking statins  
76/267
(28.5) 
59/218
(27.1) 
n/a 11/27 
(40.7) 
6/22 
(27.3) 
* Of those with a reported HbA1c. † Systolic blood pressure (BP) ≥140 mm Hg; diastolic BP ≥90 
‡ Cardiovascular complications: Includes patients categorized with coronary artery disease, angina or 
myocardial infarction. § Of those with a reported low-density lipoprotein (LDL) 
n/a: not available  
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Table 4. Patients receiving insulin, antihypertensives, and lipid-lowering medication and those who 
have reached the treatment target according to recruitment site 
 Total
n/N (%) 
 
Indonesia
n/N (%) 
Peru
n/N (%) 
Romania 
n/N (%) 
South 
Africa 
n/N (%) 
Patients on insulin 780/2068
(37.7) 
223/783
(28.5) 
120/599
(20.0) 
405/603 
(67.2) 
32/83 
(38.6) 
Patients on insulin with
a recorded HbA1c <7%  
(53 mmol/mol) 
77/780
(8.0) 
41/223
(18.4) 
15/120
(12.5) 
20/405 
(4.9) 
1/32 
(3.1) 
   
Patients on antihypertensives 711/2068
(34.4) 
199/783
(25.4) 
135/599
(22.5) 
329/603 
(54.6) 
48/83 
(57.8) 
Patients on antihypertensives 
with BP systolic <140  
& diastolic <90  
281/711
(39.5) 
58/199
(29.1) 
76/135
(56.3) 
131/329 
(39.8) 
16/48 
(33.3) 
   
Patients on statins 407/2068
(19.7) 
146/783
(18.6) 
36/599
(6.0) 
201/603 
(33.3) 
24/83 
(28.9) 
Patients on statins  
with LDL <100 mg/dL (2.6 
mmol/l) 
31/371
(8.4) 
7/146
(4.8) 
n/a 13/201 
(6.5) 
11/24 
(45.8) 
 
 
